📣 VC round data is live. Check it out!
- Public Comps
- CeriBell
CeriBell Valuation Multiples
Discover revenue and EBITDA valuation multiples for CeriBell and similar public comparables like Sunmax Biotechnology, Lumibird, Nanosonics, Advanced Medical Solutions Group and more.
CeriBell Overview
About CeriBell
CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.
Founded
2014
HQ

Employees
327
Website
Financials (LTM)
EV
$545M
Valuation Multiples
Start free trialCeriBell Financials
CeriBell reported last 12-month revenue of $100M and negative EBITDA of ($54M).
In the same LTM period, CeriBell generated $87M in gross profit, ($54M) in EBITDA losses, and had net loss of ($58M).
Revenue (LTM)
CeriBell P&L
In the most recent fiscal year, CeriBell reported revenue of $89M and EBITDA of ($50M).
CeriBell is unprofitable as of last fiscal year, with gross margin of 88%, EBITDA margin of (56%), and net margin of (60%).
Financial data powered by Morningstar, Inc.
CeriBell Stock Performance
CeriBell has current market cap of $664M, and enterprise value of $545M.
Market Cap Evolution
CeriBell's stock price is $17.50.
CeriBell share price decreased by 5.0% in the last 30 days, and by 5.4% in the last year.
CeriBell has an EPS (earnings per share) of $-1.41.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $545M | $664M | -0.6% | -5.0% | -4.5% | -5.4% | $-1.41 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCeriBell Valuation Multiples
CeriBell trades at 5.5x EV/Revenue multiple, and (10.2x) EV/EBITDA.
EV / Revenue (LTM)
CeriBell Financial Valuation Multiples
As of June 4, 2026, CeriBell has market cap of $664M and EV of $545M.
CeriBell has a P/E ratio of (11.4x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified CeriBell Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


CeriBell Margins & Growth Rates
CeriBell grew revenue by 28% and EBITDA by 12% in the last fiscal year.
In the most recent fiscal year, CeriBell reported gross margin of 88%, EBITDA margin of (56%), and net margin of (60%).
CeriBell Margins
CeriBell Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
CeriBell Operational KPIs
CeriBell's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.
CeriBell's Rule of 40 is (21%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CeriBell's Rule of X is 20% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
CeriBell Competitors
CeriBell competitors include Sunmax Biotechnology, Lumibird, Nanosonics, Advanced Medical Solutions Group, Synektik, SI-BONE, BrainsWay, SD Biosensor, Mesa Laboratories and Oculis Holding.
Most CeriBell public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 9.8x | - | 17.7x | - | |||
| 2.9x | 2.9x | 15.0x | 13.9x | |||
| 4.0x | 3.8x | 25.2x | 33.8x | |||
| 2.3x | 2.3x | 10.9x | 10.3x | |||
| 2.8x | 2.5x | 11.3x | 9.8x | |||
| 2.6x | 2.4x | 58.3x | 51.0x | |||
| 10.3x | 9.2x | 55.0x | 57.3x | |||
| 1.0x | - | (1.0x) | - | |||
This data is available for Pro users. Sign up to see all CeriBell competitors and their valuation data. Start Free Trial | ||||||
CeriBell VC Funding History
Before going public, CeriBell raised $151M in total equity funding, across 4 rounds.
Last private valuation of CeriBell was $329M, after raising $50M in September 2022 from Ally Bridge Group.
CeriBell Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout CeriBell
| When was CeriBell founded? | CeriBell was founded in 2014. |
| Where is CeriBell headquartered? | CeriBell is headquartered in United States. |
| How many employees does CeriBell have? | As of today, CeriBell has over 327 employees. |
| Who is the CEO of CeriBell? | CeriBell's CEO is Xingjuan Chao. |
| Is CeriBell publicly listed? | Yes, CeriBell is a public company listed on Nasdaq. |
| What is the stock symbol of CeriBell? | CeriBell trades under CBLL ticker. |
| When did CeriBell go public? | CeriBell went public in 2024. |
| Who are competitors of CeriBell? | CeriBell main competitors include Sunmax Biotechnology, Lumibird, Nanosonics, Advanced Medical Solutions Group, Synektik, SI-BONE, BrainsWay, SD Biosensor, Mesa Laboratories, Oculis Holding. |
| What is the current market cap of CeriBell? | CeriBell's current market cap is $664M. |
| What is the current revenue of CeriBell? | CeriBell's last 12 months revenue is $100M. |
| What is the current revenue growth of CeriBell? | CeriBell revenue growth (NTM/LTM) is 28%. |
| What is the current EV/Revenue multiple of CeriBell? | Current revenue multiple of CeriBell is 5.5x. |
| Is CeriBell profitable? | No, CeriBell is not profitable. |
| What is the current EBITDA of CeriBell? | CeriBell has negative EBITDA and is not profitable. |
| What is CeriBell's EBITDA margin? | CeriBell's last 12 months EBITDA margin is (54%). |
| What is the current EV/EBITDA multiple of CeriBell? | Current EBITDA multiple of CeriBell is (10.2x). |
| What is the current FCF of CeriBell? | CeriBell's last 12 months FCF is ($46M). |
| What is CeriBell's FCF margin? | CeriBell's last 12 months FCF margin is (47%). |
| What is the current EV/FCF multiple of CeriBell? | Current FCF multiple of CeriBell is (11.8x). |
| How many companies CeriBell has acquired to date? | CeriBell hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies CeriBell has invested to date? | CeriBell hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to CeriBell
Lists including CeriBell
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.